Repurposing of Empagliflozin as Cardioprotective Drug: An in-silico Approach.

Jyoti Yadav, Farogh Ahsan, Prabhudatta Panda, Tarique Mahmood, Shahzadi Bano, Arshiya Shamim, Pooja Mishra
{"title":"Repurposing of Empagliflozin as Cardioprotective Drug: An in-silico Approach.","authors":"Jyoti Yadav, Farogh Ahsan, Prabhudatta Panda, Tarique Mahmood, Shahzadi Bano, Arshiya Shamim, Pooja Mishra","doi":"10.2174/011871529X341930241206063315","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug repurposing involves investigating new indications or uses for drugs that have already been approved for clinical use. Empagliflozin is a C-glycosyl compound characterized by the presence of a beta-glucosyl residue. It functions as a sodium-glucose co-transporter 2 inhibitor and is utilized to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. Additionally, it is indicated for the reduction of cardiovascular mortality risk in adult patients who have both type 2 diabetes mellitus and pre-existing cardiovascular disease.</p><p><strong>Objective: </strong>The study's objective revolves around exploring the repurposing potential of a novel SGLT2 inhibitor acting as an antidiabetic drug named Empagliflozin through computational methods, with a specific focus on its interaction with cardioprotective key target proteins.</p><p><strong>Methods: </strong>The study was performed by docking the empagliflozin with different target proteins (NHE1- CHP1, BIRC5, GLUT1, and XIAP) by using Autodock, and different values were recorded. The docked files were analysed by the BIOVIA Discovery Studio Visualizer. The in silico analysis conducted in this study examines the binding free energy values of Empagliflozin with key target proteins.</p><p><strong>Results: </strong>Results revealed that NHE1-CHP1 exhibits the lowest binding free energy, followed by BIRC5, GLUT1, and XIAP, with the highest value. This descending order of binding energies suggests varying degrees of effectiveness in binding molecules, with lower energies indicative of more potent biological activity. The analysis underscores the importance of intermolecular interactions, particularly hydrogen bond formations facilitated by oxygen, nitrogen, and carbonyl groups in compound structures. Notably, NHE1-CHP1 demonstrates superior binding interactions with Empagliflozin compared to the other target proteins, highlighting its potential as a cardioprotective agent.</p><p><strong>Conclusion: </strong>These findings offer valuable insights into the therapeutic possibilities of Empagliflozin in cardioprotection, indicating promising avenues for further research and development in this domain.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011871529X341930241206063315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Drug repurposing involves investigating new indications or uses for drugs that have already been approved for clinical use. Empagliflozin is a C-glycosyl compound characterized by the presence of a beta-glucosyl residue. It functions as a sodium-glucose co-transporter 2 inhibitor and is utilized to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. Additionally, it is indicated for the reduction of cardiovascular mortality risk in adult patients who have both type 2 diabetes mellitus and pre-existing cardiovascular disease.

Objective: The study's objective revolves around exploring the repurposing potential of a novel SGLT2 inhibitor acting as an antidiabetic drug named Empagliflozin through computational methods, with a specific focus on its interaction with cardioprotective key target proteins.

Methods: The study was performed by docking the empagliflozin with different target proteins (NHE1- CHP1, BIRC5, GLUT1, and XIAP) by using Autodock, and different values were recorded. The docked files were analysed by the BIOVIA Discovery Studio Visualizer. The in silico analysis conducted in this study examines the binding free energy values of Empagliflozin with key target proteins.

Results: Results revealed that NHE1-CHP1 exhibits the lowest binding free energy, followed by BIRC5, GLUT1, and XIAP, with the highest value. This descending order of binding energies suggests varying degrees of effectiveness in binding molecules, with lower energies indicative of more potent biological activity. The analysis underscores the importance of intermolecular interactions, particularly hydrogen bond formations facilitated by oxygen, nitrogen, and carbonyl groups in compound structures. Notably, NHE1-CHP1 demonstrates superior binding interactions with Empagliflozin compared to the other target proteins, highlighting its potential as a cardioprotective agent.

Conclusion: These findings offer valuable insights into the therapeutic possibilities of Empagliflozin in cardioprotection, indicating promising avenues for further research and development in this domain.

背景:药物再利用是指研究已批准临床使用的药物的新适应症或用途。Empagliflozin 是一种 C-糖基化合物,其特点是存在一个 beta-葡萄糖残基。它是一种钠-葡萄糖协同转运体 2 抑制剂,用于加强确诊为 2 型糖尿病的成人患者的血糖控制。此外,它还适用于降低同时患有 2 型糖尿病和原有心血管疾病的成年患者的心血管死亡风险:本研究的目的是通过计算方法探索一种名为 Empagliflozin 的新型 SGLT2 抑制剂作为抗糖尿病药物的再利用潜力,特别关注其与心血管保护性关键靶蛋白的相互作用:研究采用 Autodock 方法将 Empagliflozin 与不同的靶蛋白(NHE1- CHP1、BIRC5、GLUT1 和 XIAP)进行对接,并记录不同的值。对接文件由 BIOVIA Discovery Studio Visualizer 进行分析。本研究进行的硅学分析检验了 Empagliflozin 与关键靶蛋白的结合自由能值:结果显示,NHE1-CHP1 的结合自由能最低,其次是 BIRC5、GLUT1 和 XIAP,结合自由能值最高。结合自由能从高到低的顺序表明,结合分子的有效性程度各不相同,结合自由能越低,表明生物活性越强。该分析强调了分子间相互作用的重要性,特别是化合物结构中的氧、氮和羰基对氢键形成的促进作用。值得注意的是,与其他靶蛋白相比,NHE1-CHP1 与 Empagliflozin 的结合相互作用更强,这凸显了其作为心脏保护剂的潜力:这些发现为 Empagliflozin 在心脏保护方面的治疗可能性提供了宝贵的见解,为这一领域的进一步研究和开发指明了前景广阔的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信